{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:58:51Z","timestamp":1781780331406,"version":"3.54.5"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"unspecified","delay-in-days":168,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced cardiotoxicity is a major contributor to long-term cardiovascular morbidity among cancer survivors. ACE inhibitors (ACEIs), angiotensin receptor blockers and beta blockers have been proposed as prophylactic therapies; however, the robustness of existing evidence is unclear. We aimed to evaluate the strength, consistency and certainty of evidence from meta-analyses of randomised controlled trials (RCTs) assessing antihypertensive agents for preventing chemotherapy-related cardiac dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an umbrella review of meta-analyses of RCTs following Preferred Reporting Items for Overviews of Reviews guidelines. Systematic searches were performed in PubMed, Embase and Cochrane Database through May 2025. Data were extracted and reanalysed using random-effects models (DerSimonian-Laird if \u226510 studies; Hartung-Knapp-Sidik-Jonkman if &lt;10). Certainty of evidence was graded using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. Primary outcomes included measures of cardiac function and structure; secondary outcomes were clinical and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>35 meta-analyses comprising 108 associations were included. Preservation of left ventricular (LV) ejection fraction was observed with ACEIs (mean difference, MD, 4.22%, 95%\u2009CI 1.56% to 6.88%; GRADE: very low) and beta blockers (MD 2.77%, 95%\u2009CI 1.40% to 4.14%; low). Beta blockers reduced ratio of the early (E-wave) to late (A-wave) velocity decline (MD 0.07, 95%\u2009CI 0.01 to 0.13; moderate). No significant effect was noted on LV dimensions or biomarkers. Beta blockers reduced incidence of heart failure (relative risk, RR, 0.29, 95%\u2009CI 0.26 to 0.34)\u2009and cardiotoxicity (RR 0.44, 95%\u2009CI 0.26 to 0.75), while ACEIs reduced arrhythmias (RR 0.17, 95%\u2009CI 0.03 to 0.91); certainty was low. No significant impact was detected on all-cause mortality or hypotension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ACEIs and beta blockers appear to confer modest cardioprotective effects during chemotherapy, particularly regarding systolic function and heart failure incidence, although with predominantly low-certainty evidence. Larger, robust RCTs with standardised endpoints are required before routine prophylactic use is recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD420251046471.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2026-004062","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:50:17Z","timestamp":1781779817000},"page":"e004062","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Cardioprotective role of antihypertensive treatment in chemotherapy-induced cardiotoxicity: umbrella review of meta-analyses of randomised controlled trials"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6651-1354","authenticated-orcid":false,"given":"Aghil","family":"Rostami","sequence":"first","affiliation":[{"name":"Non-Communicable Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-995X","authenticated-orcid":false,"given":"Haleh","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hosseininasab","sequence":"additional","affiliation":[{"name":"Artificial Intelligence in Health Research Center, Iran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"2026061803500947000_13.1.e004062.1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","article-title":"Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?","volume":"185","author":"Dempke","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026061803500947000_13.1.e004062.2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092885","article-title":"Management of Cardiac Toxicity Induced by Chemotherapy","volume":"9","author":"Trapani","year":"2020","journal-title":"J Clin Med"},{"key":"2026061803500947000_13.1.e004062.3","first-page":"244","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"133","author":"Armenian","year":"2016","journal-title":"Circulation"},{"key":"2026061803500947000_13.1.e004062.4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/ehf2.15095","article-title":"Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy","volume":"12","author":"Colombo","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026061803500947000_13.1.e004062.5","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","article-title":"A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer","volume":"43","author":"Lewinter","year":"2022","journal-title":"Eur Heart J"},{"key":"2026061803500947000_13.1.e004062.6","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-019-09906-x"},{"key":"2026061803500947000_13.1.e004062.7","article-title":"Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis","volume":"9","author":"Mir","year":"2023","journal-title":"Cardiooncology"},{"key":"2026061803500947000_13.1.e004062.8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10557-023-07457-w","article-title":"Comparing Renin-Angiotensin-Aldosterone Blockade Regimens for Long-Term Chemotherapy-Related Cardiac Dysfunction: A Network Meta-Analysis","volume":"39","author":"Li","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026061803500947000_13.1.e004062.9","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8367444","article-title":"Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials","volume":"2022","author":"Attar","year":"2022","journal-title":"Cardiovasc Ther"},{"key":"2026061803500947000_13.1.e004062.10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejca.2022.03.024","article-title":"Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis","volume":"169","author":"Sayed","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026061803500947000_13.1.e004062.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement","volume":"378","author":"Gates","year":"2022","journal-title":"BMJ"},{"key":"2026061803500947000_13.1.e004062.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072348","article-title":"Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies","volume":"382","author":"Solmi","year":"2023","journal-title":"BMJ"},{"key":"2026061803500947000_13.1.e004062.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"2026061803500947000_13.1.e004062.14","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2026061803500947000_13.1.e004062.15","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026061803500947000_13.1.e004062.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026061803500947000_13.1.e004062.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.08.013"},{"key":"2026061803500947000_13.1.e004062.18","doi-asserted-by":"crossref","unstructured":"van Dalen EC , Caron HN , Dickinson HO , et al . Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008;CD003917. doi:10.1002\/14651858.CD003917.pub3","DOI":"10.1002\/14651858.CD003917.pub3"},{"key":"2026061803500947000_13.1.e004062.19","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-019-0298-6","article-title":"Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials","volume":"20","author":"Ma","year":"2019","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026061803500947000_13.1.e004062.20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.amjcard.2009.08.677","article-title":"Relation of beta-blocker use with frequency of hospitalization for heart failure in patients with left ventricular diastolic dysfunction (from the Heart and Soul Study)","volume":"105","author":"Smith","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026061803500947000_13.1.e004062.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(03)00054-0"},{"key":"2026061803500947000_13.1.e004062.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2010.04.001"},{"key":"2026061803500947000_13.1.e004062.23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.amjcard.2019.05.046","article-title":"Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function During Anthracycline Therapy","volume":"124","author":"Shah","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026061803500947000_13.1.e004062.24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncol"},{"key":"2026061803500947000_13.1.e004062.25","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeac106"},{"key":"2026061803500947000_13.1.e004062.26","doi-asserted-by":"crossref","DOI":"10.36660\/abc.20220298","article-title":"Renin-angiotensin System Antagonists and Beta-blockers in Prevention of Anthracycline Cardiotoxicity: a Systematic Review and Meta-analysis","volume":"120","author":"Avila","year":"2023","journal-title":"Arq Bras Cardiol"},{"key":"2026061803500947000_13.1.e004062.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.08.039"},{"key":"2026061803500947000_13.1.e004062.28","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-018-9755-3"},{"key":"2026061803500947000_13.1.e004062.29","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.1.31"},{"key":"2026061803500947000_13.1.e004062.30","first-page":"VII49","article-title":"The role of ACE inhibitors in the treatment of arrhythmias","volume":"13","author":"McKenna","year":"1990","journal-title":"Clin Cardiol"},{"key":"2026061803500947000_13.1.e004062.31","first-page":"e1","article-title":"Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation","volume":"14","author":"Anis","year":"2009","journal-title":"Exp Clin Cardiol"},{"key":"2026061803500947000_13.1.e004062.32","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.21037\/tcr-20-1869","article-title":"Can ACEI\/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?-a meta-analysis of randomized controlled trials","volume":"9","author":"Dong","year":"2020","journal-title":"Transl Cancer Res"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2026-004062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:50:22Z","timestamp":1781779822000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2026-004062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6,18]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/openhrt-2026-004062"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2026-004062","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}